Second Phase 3 Study of MDMA-assisted Therapy Reports Positive Results, Paving Way for New Drug Application

The Multidisciplinary Association for Psychedelic Studies (MAPS) and its Public Benefit Corp. arm, MAPS PBC, today published its second Phase 3 study (MAPP2) of MDMA-assisted therapy (MDMA-AT) for PTSD in the prestigious journal, Nature. In January 2023, MAPS announced that the study had been “successful”, confirming prior results. Now, the study’s published results show that the intervention…

Source